2-(吡啶-2-基甲基氨基)乙酸 | 2444-13-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(吡啶-2-基甲基氨基)乙酸
• 中文别名: [(吡啶-2-基甲基)-氨基]-乙酸
• 英文名称: 2-(pyridin-2-ylmethylamino)acetic acid
• 英文别名: 2-(Aminomethyl)-pyridin-N-monoessigsaeure；N-(2-pyridylmethyl)-L-glycine；2-[1-(pyridin-2-yl)methylamino]acetic acid；N-pyridin-2-ylmethyl-glycine；pyridinemethylamine monoacetic acid；Hpgly；2-(Pyridin-2-ylmethylazaniumyl)acetate
• CAS: 2444-13-5
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD08443553
• 分子量: 166.18
• InChiKey: MDMCWJVDDJDEGI-UHFFFAOYSA-N

物化性质

• 熔点：
  209-210 °C (decomp)
• 沸点：
  323.9±27.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-(吡啶-2-基甲基氨基)乙酸 、 N,N-二乙基氯乙胺 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以24%的产率得到2-[(2-(diethylamino)ethyl)(pyridin-2-ylmethyl)amino]acetic acid
  参考文献：
  名称：

  99mTc(I)/Re(I) tricarbonyl complexes for in vivo targeting of melanotic melanoma: Synthesis and biological evaluation

  摘要：

  The Tc-99m (I) tricarbonyl complexes fac-[Tc-99m(kappa(3)-L)(CO)(3)] (Tc1-Tc6) containing N-ethylpyrrolidine and N,N-diethylethylamine groups for melanin binding, were evaluated in vitro and in vivo as radioactive probes for the targeting of melanotic melanoma. Aiming at the modification of their size, topology and lipophilicity, Tc1-Tc6 were obtained based on an S,N,O-donor bifunctional chelator (BFC) derived from cysteamine and on pyridyl- and pyrazolyl-containing N,N,O-donor BFCs. Tc1-Tc6 were chemically identified by HPLC comparison with the Re congeners (Re1-Re6) that were synthesized at the macroscopic level and fully characterized by common analytical techniques. With the exception of Tc5 and Tc6, these Tc-99m complexes are moderately lipophilic, and bind to melanin with moderate to high affinity (23-87%). The cell uptake of Tc1-Tc6, expressed as a percentage of total activity per million cells, spanned between 0.86 and 21.02% for the melanotic B16-F1 cell line and between 0.49% and 13.58% for the amelanotic A375 cell line. In the B16-F1 cell line, Tc1, Tc3 and Tc4 showed moderate cellular uptake values (>10% at 4 h of incubation). In the amelanotic A375 cell line, only Tc4 has shown a moderate cell uptake (>10% at 4 h of incubation), with all the other compounds displaying a relatively poor uptake, i.e. inferior to 5%. Competition studies with haloperidol have shown that the involvement of sigma receptors in cellular uptake and retention is likely to occur for Tc4. Complex Tc1, stabilized with the S,N,O-donor BFC and containing a N,N-diethylethylamine group, presented the most promising biological profile for in vivo targeting of melanoma, showing a moderate tumor uptake of 2.17% ID/g at 1 h p.i in a B16-F1 melanoma-bearing mouse and rather favorable target/non-target ratios with values as high as 16.9 and 5.2 for tumor/muscle and tumor/blood ratios, respectively. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.014

文献信息

• COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS
  申请人：Mahmood Ashfaq

  公开号：US20120269724A1

  公开（公告）日：2012-10-25

  The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.

  本发明涉及化合物及其相关的锝和铼配合物，适用于组织、器官或肿瘤的成像或治疗。在另一实施例中，本发明涉及使用放射标记的金属配合物成像组织、器官或肿瘤的方法，特别是那些表达本发明化合物或配合物具有亲和力的特定受体的组织、器官或肿瘤。本发明还涉及治疗癌症的方法，特别是那些表达本发明化合物或配合物具有亲和力的特定受体的癌细胞系。在另一实施例中，本发明提供了使用具有与待成像和/或抑制的受体或神经受体具有亲和力的本发明化合物或配合物成像和/或抑制受体或神经受体的方法。
• INHIBITORS OF CARBONIC ANHYDRASE IX
  申请人：Zimmerman Craig

  公开号：US20090175794A1

  公开（公告）日：2009-07-09

  Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:

  具有在诊断成像和治疗过度表达CA-IX疾病中有用的新型放射性药物，包括一种含有磺胺基团的复合物，该基团能够结合CA-IX的活性催化位点，以及适用于放射成像和/或放射治疗的放射性核素：
• Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
  申请人：Escaich Sonia

  公开号：US20100022541A1

  公开（公告）日：2010-01-28

  The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR 1 , C1-C10 alkyl-NR 1 R 1 , alkoxy, hydroxy, thioalkyl, aryl, heterocycle, halogen, nitro, cyano, CO 2 R 1 , NR 1 R 1 , NR 1 C(O)R 1 , C(O)NR 1 R 1 , NR 1 C(S)R 1 , C(S)NR 1 R 1 , SO 2 NR 1 R 1 , SO 2 R 1 , NR 1 SO 2 R 1 , NR 1 C(O)NR 1 R 1 , NR 1 C(O)OR 1 , NR 1 C(S)NR 1 R 1 , NR 1 C(S)OR 1 , R 1 C═NOR 1 , C(O)R 1 , aryloxy, thioaryl, alkenyl, alkynyl R1 identical or different is H or C1-C10 alkyl B 1 , B 2 , B 3 identical or not represent C, N, O, S to form a five-membered aromatic ring wherein from one to three carbon atoms are replaced by a heteroatom selected from S, O, N optionally substituted by one or several identical or different R such as defined above B 4 is C or N Y is H, C1-C10 alkyl, alkoxy, thio-alkyl, optionally substituted by one or several identical or different R such as defined above W is C, O or N, substituted or not by one or several C1-C10 alkyl radicals D is an heterocycle optionally substituted by one or several identical or different R such as defined above.

  本发明涉及具有抑制庚糖合成特性的新化合物，其具有式(I)或其药学上可接受的盐或前药，其中A为芳基或杂环，任选地被一个或多个相同或不同的R取代，如H、C1-C10烷基、C1-C10烷基-OR1、C1-C10烷基-NR1R1、烷氧基、羟基、硫代烷基、芳基、杂环、卤素、硝基、氰基、CO2R1、NR1R1、NR1C(O)R1、C(O)NR1R1、NR1C(S)R1、C(S)NR1R1、SO2NR1R1、SO2R1、NR1SO2R1、NR1C(O)NR1R1、NR1C(O)OR1、NR1C(S)NR1R1、NR1C(S)OR1、R1C═NOR1、C(O)R1、芳氧基、硫代芳基、烯基、炔基，R1相同或不同为H或C1-C10烷基；B1、B2、B3相同或不同，代表C、N、O、S以形成五元芳香环，其中一到三个碳原子被选自S、O、N的杂原子替换，任选地被一个或多个相同或不同的如上定义的R取代；B4为C或N；Y为H、C1-C10烷基、烷氧基、硫代烷基，任选地被一个或多个相同或不同的如上定义的R取代；W为C、O或N，被或不被一个或多个C1-C10烷基基团取代；D为任选地被一个或多个相同或不同的如上定义的R取代的杂环。
• Photocrosslinked hydrogel blend surface coatings
  申请人：Huang Wenxi

  公开号：US20050059086A1

  公开（公告）日：2005-03-17

  Hydrogel polymer blends including precursors and crosslinked forms of the compositions. The blends provide an improved approach to achieve high quality, uniform coatings with better commercial viability than other approaches including copolymerization. Applications include mass spectral analysis of biomolecular analytes such as proteins. Dextran and acrylamide systems are preferred. Benzophenone groups can be used as photocrosslinking groups. Photoinitiators are not needed. Functionalities which can selectively bind to biomolecular analytes are included.

  氢凝胶聚合物混合物包括前体和交联形式的组合物。这些混合物提供了一种改进的方法，可以实现高质量、均匀涂层，比其他方法（包括共聚合）具有更好的商业可行性。应用包括蛋白质等生物分子的质谱分析。葡聚糖和丙烯酰胺系统是首选。苯甲酮基团可用作光交联基团。不需要光引发剂。包括能够选择性结合生物分子分析物的功能基团。
• [EN] SELECTIVE SEPRASE INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE LA SÉPRASE
  申请人：MOLECULAR INSIGHT PHARM INC

  公开号：WO2010036814A1

  公开（公告）日：2010-04-01

  Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy (Formulae I & II).

  具有识别成像和治疗超表达丝氨酸酶疾病特征的新型放射性药物包括含有脯氨酸部分和适用于放射成像和/或放射治疗的放射性核素的复合物（公式I和II）。